Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2016-08-08 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
CPEng
Regulatory Filings Classification · 95% confidence The document is an announcement from AB Science SA dated August 8, 2016, detailing that the European Medicines Agency (EMA) granted Orphan Drug Designation to Masitinib for the treatment of Amyotrophic Lateral Sclerosis (ALS). This is a specific regulatory/scientific development announcement concerning a drug candidate, not a comprehensive annual report (10-K), quarterly report (IR), earnings release (ER), or a general regulatory filing (RNS). It is a specific update on regulatory progress. While it relates to drug development, it is not a general management/board change (MANG) or a legal proceeding (LTR). It is best classified as a specific regulatory/scientific update. Since there isn't a perfect category for 'Drug Regulatory Milestone,' I must choose the closest fit. It is not a standard financial filing like 10-K or ER. It is an announcement of a specific regulatory event. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for specific, non-standard regulatory news that doesn't fit the other defined categories (like DIRS, DIV, CAP, etc.). However, the content is highly specific to drug development progress, which often falls under general investor relations news. Since it is a press release announcing a specific regulatory achievement (Orphan Drug Status), and not a general regulatory filing, I will re-evaluate. It is not a Call Transcript (CT), Investor Presentation (IP), or Management Discussion (MDA). It is a press release announcing a significant event. Given the strict definitions, and noting that this is a specific announcement about a drug status, it is not a standard financial report. It is closest to a general announcement. I will use RNS as the general regulatory announcement fallback, as it details an interaction with a regulatory body (EMA).
2016-08-08 English
Validation du plan d'action
Legal Proceedings Report Classification · 99% confidence The document is a press release dated July 15, 2016, announcing that the FDA has approved AB Science's action plan to address a previous warning letter. It details regulatory compliance steps and mentions other positive FDA interactions (compassionate use authorization). This type of announcement, focusing on regulatory correspondence and compliance status rather than full financial results (ER/IR) or a formal legal filing, fits best under general Regulatory Filings (RNS) or potentially Legal Proceedings Report (LTR) if the warning letter was considered a major legal/regulatory action. However, since it is an announcement about regulatory compliance validation, RNS serves as the most appropriate general regulatory announcement category, as it is not a formal financial report, management change, or specific legal filing document itself. Given the short length and nature as an announcement, RNS is preferred over LTR.
2016-07-15 English
Validation du plan d'action
Legal Proceedings Report Classification · 99% confidence The document is a press release dated July 15, 2016, announcing that the FDA has approved AB Science's action plan to address a previous warning letter. It details regulatory compliance steps and mentions other positive FDA interactions (compassionate use authorization). This type of announcement, focusing on regulatory correspondence and compliance status rather than full financial results (ER/IR) or a formal legal filing, fits best under general Regulatory Filings (RNS) or potentially Legal Proceedings Report (LTR) if the warning letter was considered a major legal/regulatory action. However, since it is an announcement about regulatory compliance validation, RNS serves as the most appropriate general regulatory announcement category, as it is not a formal financial report, management change, or specific legal filing document itself. Given the short length and nature as an announcement, RNS is preferred over LTR.
2016-07-15 French
CP14.07.16
Regulatory Filings Classification · 95% confidence The document is an announcement from AB Science regarding validation of its action plan by the FDA following a warning letter. It discusses regulatory compliance, specific drug development milestones (masitinib), and provides general company information. This type of communication, focusing on regulatory interactions and operational updates rather than comprehensive financial results (10-K, IR, ER) or management changes (MANG), fits best under general Regulatory Filings (RNS) or potentially Legal Proceedings Report (LTR) due to the FDA warning letter context. However, since it is a positive update on regulatory compliance and not a formal legal filing or a standard financial report, RNS serves as the most appropriate general regulatory announcement category, as it doesn't fit the specific definitions for AGM-R, 10-K, AR, CT, CAP, DVA, DLST, DIRS, ER, SR, FS, CGR, IRAT, IR, IP, LTR (though close), TAR, MRQ, MDA, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS. Given the content is a specific regulatory update, RNS is the best fit as a miscellaneous regulatory announcement.
2016-07-14 English
CPEng
Regulatory Filings Classification · 95% confidence The document is a press release dated July 11, 2016, announcing that the FDA granted compassionate use for the drug masitinib for an ALS patient. It details the drug, the company (AB Science), and its pipeline. This type of announcement, focusing on a specific regulatory or clinical event (FDA approval for compassionate use), is not a standard periodic report (10-K, IR, ER) nor a formal shareholder communication (DEF 14A, AGM-R). It is a specific update regarding regulatory interaction and drug development progress. Since it is not a formal financial report, a management discussion, or a specific legal/insider filing, it best fits the general category for regulatory or significant company news that doesn't fit elsewhere, which is Regulatory Filings (RNS). It is not a Report Publication Announcement (RPA) because it is the primary news release, not an announcement *about* another report.
2016-07-11 English
CPFR
Regulatory Filings Classification · 95% confidence The document is a press release dated July 11, 2016, announcing that the FDA has approved an Investigational New Drug (IND) application for compassionate use of the drug masitinib for a patient with Amyotrophic Lateral Sclerosis (ALS). This is a specific announcement regarding regulatory interaction (FDA approval for compassionate use) and drug development progress, rather than a comprehensive financial report (like 10-K or IR) or a general earnings release (ER). It is a specific regulatory/development update. Given the options, this type of announcement, which details a specific regulatory action concerning a drug's development pathway, fits best under 'Regulatory Filings' (RNS) as a general regulatory announcement, or potentially 'LTR' if viewed as a legal/regulatory matter, but RNS is the most appropriate fallback for specific, non-financial regulatory news that doesn't fit other categories like M&A or Director's Dealing. Since it is a specific announcement about a regulatory decision (FDA IND approval), and not a standard financial report, RNS is the best fit as a general regulatory communication.
2016-07-11 French

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.